Linneo Health appoints Don Bellamy as Chief Executive Officer

Experienced executive bringing over 30 years’ pharmaceuticals and regulated cannabis industry knowledge

Madrid, Spain 29 September 2021: Linneo Health, a global leader in the research, cultivation and supply of cannabis to improve human health and wellbeing, today announces the appointment of Don Bellamy as Chief Executive Officer.

Don is a highly experienced executive having worked within the pharmaceutical and regulated cannabis industries for over 30 years, including his role as Senior Vice President – Medical Products, at Canopy Growth (TSX: WEED) in Canada, where he was responsible for the global strategic and operational development of Spectrum Cannabis and Canopy’s medical prescription business. He also founded the life sciences and medical cannabis consulting firm, Goodfriend Consulting.

Don started his career in the pharmaceutical sector, where he held several positions of increasing responsibility in Baxalta-Shire, Novartis and AstraZeneca. He has extensive experience in global roles, general management, marketing, and business operations. As Global Head of Marketing and Launch Excellence at Baxalta-Shire, he implemented a standardized launch process for the company, estimated to have added $1bn in topline sales. As Business Services Director for Canada and Latin America for Novartis, he helped to deliver over $30m in operational savings after one year, and retuned the company’s mature portfolio of products back to growth. At AstraZeneca, he established its first affiliate in Colombia and turned it into the fastest growing multinational over two consecutive years.

Don holds a MA Hons in Economics from The University of St. Andrews, Scotland.

Don Bellamy, Chief Executive Officer of Linneo Health, commented: “Linneo is a leader in the medicinal cannabis space, providing the highest quality product for partners developing cannabis-based therapies for people in need. I am proud to be joining such a dynamic team, and a company backed by over 90 years’ experience in handling controlled substances. Linneo is committed to providing exceptional quality medicinal cannabis to both its existing and future partners for the benefit of patients around the world and I look forward to helping drive this mission and to support the development of innovative products.”

Alan Mackay, Chairman of Linneo Health, added: “Don brings a wealth of knowledge and experience to Linneo Health from his decades working in the pharmaceutical and medical cannabis industries. Under Don’s leadership I am convinced Linneo Health will further expand our expertise and offering of medicinal cannabis to our reputable partners who are developing life-saving therapies and products around the world.”